文献速递肝病

经验性抗真菌治疗改善慢加急性肝衰竭疑似侵袭性真菌感染患者生存:一项实用性随机试验

Empirical Antifungal Therapy Improves Survival in Patients With Acute-on-Chronic Liver Failure With Suspected Invasive Fungal Infections: A Pragmatic Randomized Trial.
PubMed 文献 · Am J Gastroenterol · 2025-11-21

该平行组实用性随机试验纳入216例具有预设宿主和临床真菌感染因素的住院ACLF患者,1:1比较入组时经验性抗真菌治疗与基于诊断/生物标志物的抢先治疗。经验性治疗组28天总生存率显著提高(35% vs 13%;HR 0.64,95%CI 0.47-0.88;P=0.005),治疗成功率和IFI缓解率更高,院内及IFI归因死亡率更低,不良事件更少且质量调整生命年增益更大。

要点

  • 经验性抗真菌治疗较诊断驱动抢先治疗显著改善28天生存(35% vs 13%;HR 0.64;P=0.005)。
  • 经验性组治疗成功率37.4% vs 16.9%(P=0.002),IFI缓解率45.8% vs 22.5%(P=0.001)。
  • 40岁以上、合并心血管衰竭但无呼吸衰竭的患者生存获益最大。

核心结论

  • 在结构化抗菌药物管理框架下,早期经验性抗真菌治疗可改善ACLF合并疑似IFI患者的生存。

研究设计与样本

  • 平行组、实用性、随机对照试验,终点裁定设盲(NCT04157465),纳入216例具有预设IFI宿主和临床因素的住院ACLF患者,1:1随机分组。

主要发现

  • 经验性组28天总生存率35%,诊断/生物标志物驱动抢先治疗组13%(HR 0.64,95%CI 0.47-0.88;P=0.005)。
  • 经验性组治疗成功率37.4% vs 16.9%(P=0.002),IFI缓解率45.8% vs 22.5%(P=0.001)。
  • 经验性组院内及IFI归因死亡率55.6% vs 75.9%(P=0.003),不良事件更少,质量调整生命年增益29.9 vs 10.1,增量成本效果比为国际标准化比值1,42,737。
  • 40岁及以上、合并心血管衰竭但无呼吸衰竭的患者生存获益最大。

临床怎么用

  • 对具有预设IFI宿主和临床因素的ACLF住院患者,可考虑在结构化抗菌药物管理框架下尽早启动经验性抗真菌治疗。
  • 治疗决策需结合 timely recognition、快速诊断和个体化抗真菌策略,以桥接患者至恢复或确定性治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Invasive fungal infections (IFIs) in acute-on-chronic liver failure (ACLF) are associated with transplant delistings, high morbidity, and mortality. An optimal strategy of antifungal therapy in this setting remains uncertain. We compared suspicion-based (empirical) with investigation-driven (diagnostic/biomarker-driven-pre-emptive) antifungal therapy among patients with ACLF in a high-burden setting. METHODS: In this parallel-group, pragmatic, randomized trial with blinded endpoint adjudication (NCT04157465), 216 hospitalized ACLF patients with predefined host and clinical factors for IFI were randomized (1:1) to empirical antifungal therapy at enrolment or diagnostic/biomarker-driven-pre-emptive therapy on laboratory, radiological, or mycological confirmation. Biomarker-guided and culture-guided antifungal stewardship protocols were implemented in both groups. The primary outcome was 28-day overall survival. Secondary outcomes included in-hospital mortality, changes in severity scores, adverse events, and cost-effectiveness. Heterogeneous treatment effects were explored through causal tree analysis. RESULTS: Empirical antifungal therapy significantly improved 28-day survival compared with diagnostic/biomarker-driven-pre-emptive therapy (35% vs 13%; hazard ratio: 0.64, 95% confidence interval: 0.47-0.88; P = 0.005). Treatment success (37.4% vs 16.9%; P = 0.002) and IFI resolution (45.8% vs 22.5%, P = 0.001) were higher; in-hospital and IFI-attributable mortality (55.6% vs 75.9%; P = 0.003) was lower in the empirical group. Fewer adverse events with greater quality-of-life years gains (29.9 vs 10.1) and an incremental cost-effectiveness ratio of international normalized ratio 1,42,737 were observed with empirical therapy. The survival benefit was maximum among patients aged 40 years or older with cardiovascular failure but without respiratory failure. DISCUSSION: Early empirical antifungal therapy within a structured stewardship framework improves survival in patients with ACLF and IFIs. Timely recognition, rapid diagnostics, and individualized antifungal strategies are essential to bridge these high-risk patients toward recovery or definitive therapies.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Verma N, Valsan A, Garg P, et al. Empirical Antifungal Therapy Improves Survival in Patients With Acute-on-Chronic Liver Failure With Suspected Invasive Fungal Infections: A Pragmatic Randomized Trial. Am J Gastroenterol. 2025. PMID: 41268913. doi:10.14309/ajg.0000000000003832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。